Guideline development for the management of gout: role of combination therapy with a focus on lesinurad.

about

Urate transporter inhibitor lesinurad is a selective peroxisome proliferator-activated receptor gamma modulator (sPPARγM) in vitro

P2860

Q58756051-5DAD4B70-838F-4022-AFD1-DB6001000E95

P2860

Guideline development for the management of gout: role of combination therapy with a focus on lesinurad.

Item

http://www.wikidata.org/entity/Q47104482

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年学术文章

@wuu

2017年学术文章

@zh

2017年学术文章

@zh-cn

2017年学术文章

@zh-hans

2017年学术文章

@zh-my

2017年学术文章

@zh-sg

2017年學術文章

@yue

2017年學術文章

@zh-hant

name

Guideline development for the ...... apy with a focus on lesinurad.

@en

Guideline development for the ...... apy with a focus on lesinurad.

@nl

type

Item

label

Guideline development for the ...... apy with a focus on lesinurad.

@en

Guideline development for the ...... apy with a focus on lesinurad.

@nl

prefLabel

Guideline development for the ...... apy with a focus on lesinurad.

@en

Guideline development for the ...... apy with a focus on lesinurad.

@nl

P1476

Guideline development for the ...... apy with a focus on lesinurad.

@en

P2093

Elena Panova

http://www.w3.org/2001/XMLSchema#string

Graeme Jones

http://www.w3.org/2001/XMLSchema#string

P275

Creative Commons Attribution-NonCommercial

P2860

Allopurinol for chronic gout

2012 American College of Rheumatology guidelines for management of gout. Part 1: systematic nonpharmacologic and pharmacologic therapeutic approaches to hyperuricemia

The genetics of hyperuricaemia and gout

Lesinurad in combination with allopurinol: results of a phase 2, randomised, double-blind study in patients with gout with an inadequate response to allopurinol

Medication adherence in gout: a systematic review

2016 updated EULAR evidence-based recommendations for the management of gout.

Efficacy and tolerability of urate-lowering drugs in gout: a randomised controlled trial of benzbromarone versus probenecid after failure of allopurinol.

Lesinurad, a Selective Uric Acid Reabsorption Inhibitor, in Combination With Febuxostat in Patients With Tophaceous Gout: Findings of a Phase III Clinical Trial.

Lesinurad Combined With Allopurinol: A Randomized, Double-Blind, Placebo-Controlled Study in Gout Patients With an Inadequate Response to Standard-of-Care Allopurinol (a US-Based Study).

Using allopurinol above the dose based on creatinine clearance is effective and safe in patients with chronic gout, including those with renal impairment.

P304

3077-3081

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

review article

P356

10.2147/DDDT.S97959

http://www.w3.org/2001/XMLSchema#string

P407

English

P478

http://www.w3.org/2001/XMLSchema#string

P50

Richard Day

P5008

ScienceSource

P577

2017-10-24T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

29123379

http://www.w3.org/2001/XMLSchema#string

P921

gout

carboxylic acid

P932

5661481

http://www.w3.org/2001/XMLSchema#string

Guideline development for the management of gout: role of combination therapy with a focus on lesinurad.

about

P2860

P2860

Guideline development for the management of gout: role of combination therapy with a focus on lesinurad.

description

name

type

label

prefLabel

P1433

P1476

P2093

P275

P2860

P304

P31

P356

P407

P478

P50

P5008

P577

P698

P921

P932

P356

P1433

P1476

P2093

P275

P2860

P304

P31

P356

P407

P478

P50

P5008

P577

P698

P921

P932